Susquehanna Fundamental Investments’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-246,001	Closed	-$386K	–	1585
2022 Q3	$386K	Buy	+246,001	New	+$558K	0.01%	1089
2022 Q1	$573K	Buy	246,001 +185,701	+308%	+$579K	0.01%	1020
2021 Q4	$280K	Buy	+60,300	New	+$374K	0.01%	1135
2021 Q2	–	Sell	-55,986	Closed	-$463K	–	1827
2021 Q1	$463K	Buy	+55,986	New	+$591K	0.01%	1167

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Susquehanna Fundamental Investments's SRNE Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 246,001 shares — an estimated $386K sold.

Susquehanna Fundamental Investments first reported a position in SRNE in Q1 2021 and held it in 4 quarters. The position peaked at $573K in Q1 2022. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 246,001 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $386K.
Susquehanna Fundamental Investments first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 4 quarters.
Susquehanna Fundamental Investments's Sorrento Therapeutics, Inc. position peaked at $573K in Q1 2022.
223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.